Tag: NVX-CoV2373

Novavax reports success for NVX-CoV2373 in pediatric group of phase 3 trial

pallavi123- February 13, 2022

Novavax said that its Covid-19 vaccine NVX-CoV2373 achieved its primary effectiveness endpoint in the pediatric expansion of its phase 3 PREVENT-19 trial. According to the ... Read More

Novavax begins phase 3 trial of NVX-CoV2373 COVID-19 vaccine candidate

pharmanewsdaily- September 25, 2020

Novavax has initiated its first phase 3 clinical trial to assess the efficacy, safety, and immunogenicity of its NVX-CoV2373 COVID-19 vaccine candidate. The US vaccine ... Read More

Takeda strikes deal to bring Novavax’ NVX‑CoV2373 COVID-19 vaccine to Japan

pharmanewsdaily- August 8, 2020

US-based pharma company Novavax and Takeda Pharmaceutical have joined forces for the development, manufacturing, and commercialization of NVX‑CoV2373, the former's COVID‑19 vaccine candidate, in Japan. ... Read More

Novavax NVX-CoV2373 COVID-19 vaccine candidate to be manufactured by FDB

pharmanewsdaily- July 24, 2020

Novavax has signed an agreement with FUJIFILM Diosynth Biotechnologies (FDB), a US-based contract development and manufacturing organization (CDMO), for the manufacturing of bulk drug substance ... Read More